Trial reportJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2014
Serotonin 2A receptor agonist binding in the human brain with [¹¹C]Cimbi-36.
Trial report in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Effects of bariatric surgery and dietary interventions for obesity on brain neurotransmitter systems and metabolism: A systematic review of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) studies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2023Pooled it
- Measuring endogenous changes in serotonergic neurotransmission with [Translational psychiatry · 2019Trial
- Trial
- LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.Human brain mapping · 2016Trial
- Article
- Discordance Between Spatial and Population Correlations From Human Brain Imaging Data.Human brain mapping · 2025Article
- Imaging the 5-HTJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2025Article
- Multimodal brain age prediction using machine learning: combining structural MRI and 5-HT2AR PET-derived features.GeroScience · 2024Article
- Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics.Neuroscience insights · 2024Article
- Concise and Scalable Radiosynthesis of (+)-[ACS chemical neuroscience · 2023Article
- Neuroimaging in psychedelic drug development: past, present, and future.Molecular psychiatry · 2023Review
- The promises and perils of psychedelic pharmacology for psychiatry.Nature reviews. Drug discovery · 2022Review
- Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals.Journal of psychopharmacology (Oxford, England) · 2022Article
- Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals.Frontiers in psychology · 2022Article
- NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
- Opposite alterations of 5-HTTranslational psychiatry · 2021Article
- Radiosynthesis and Biological Evaluation of [ACS medicinal chemistry letters · 2021Article
- Translational PET applications for brain circuit mapping with transgenic neuromodulation tools.Pharmacology, biochemistry, and behavior · 2021Review
- 25CN-NBOMe Metabolites in Rat Urine, Human Liver Microsomes andMetabolites · 2021Article
- International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.Pharmacological reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[(11)C]Cimbi-36 was recently developed as a selective serotonin 2A (5-HT(2A)) receptor agonist radioligand for positron emission tomography (PET) brain imaging. Such an agonist PET radioligand may provide a novel, and more functional, measure of the serotonergic system and agonist binding is more likely than antagonist binding to reflect 5-HT levels in vivo. Here, we show data from a first-in-human clinical trial with [(11)C]Cimbi-36. In 29 healthy volunteers, we found high brain uptake and distribution according to 5-HT(2A) receptors with [(11)C]Cimbi-36 PET. The two-tissue compartment model using arterial input measurements provided the most optimal quantification of cerebral [(11)C]Cimbi-36 binding. Reference tissue modeling was feasible as it induced a negative but predictable bias in [(11)C]Cimbi-36 PET outcome measures. In five subjects, pretreatment with the 5-HT(2A) receptor antagonist ketanserin before a second PET scan significantly decreased [(11)C]Cimbi-36 binding in all cortical regions with no effects in cerebellum. These results confirm that [(11)C]Cimbi-36 binding is selective for 5-HT(2A) receptors in the cerebral cortex and that cerebellum is an appropriate reference tissue for quantification of 5-HT(2A) receptors in the human brain. Thus, we here describe [(11)C]Cimbi-36 as the first agonist PET radioligand to successfully image and quantify 5-HT(2A) receptors in the human brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.